Lenalidomide
Showing 1 - 25 of 1,173
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +
Not yet recruiting
- Marginal Zone Lymphoma
- Mosunetuzumab + Lenalidomide
- +3 more
- (no location specified)
Aug 16, 2023
Multiple Myeloma Trial in Canton (Lenalidomide)
Recruiting
- Multiple Myeloma
- Lenalidomide
-
Canton, OhioGabrail Cancer & Research Center
Oct 11, 2023
MDS Trial in Beijing (Lenalidomide, Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Lenalidomide
- Azacitidine
-
Beijing, ChinaPeking union medical college hospital
Aug 16, 2023
Based on Quantitative Pharmacology in Patients With Lenalidomide
Recruiting
- Multiple Myeloma
- +2 more
-
Jinan, Shandong, Chinathe First Affiliated Hospital of Shandong First Medical Universi
Oct 3, 2023
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lenalidomide combined with G-CHOP (LO CHOP)
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Selinexor Combined With Lenalidomide and Rituximab in Treatment
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- Selinexor combined with lenalidomide and rituximab
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 20, 2023
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
Tafasitamab in Combination With Lenalidomide in Patients withR/R
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Tafasitamab Injection
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 31, 2023
Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)
Not yet recruiting
- Multiple Myeloma
- Isatuximab
- lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2023
Advanced HCC Trial (Lenalidomide)
Not yet recruiting
- Advanced HCC
- Lenalidomide
- (no location specified)
Apr 16, 2023
Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)
Recruiting
- Marginal Zone Lymphoma
- Obinutuzumab, lenalidomide
-
Tianjin, Tian, ChinaInstitute of Hematology & Blood Diseases Hospital
Apr 27, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
B-cell Non-Hodgkin's Lymphoma Trial (IMM0306, Lenalidomide capsule)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- IMM0306
- Lenalidomide capsule
- (no location specified)
Mar 6, 2023
Multiple Myeloma, Cancer, Hematologic Cancer Trial in Cork (Discontinuation of maintenance treatment)
Not yet recruiting
- Multiple Myeloma
- +2 more
- Discontinuation of maintenance treatment
-
Cork, IrelandCork University Hospital
May 10, 2023
Multiple Myeloma Trial in Rennes (Blood and bone marrow sampling)
Completed
- Multiple Myeloma
- Blood and bone marrow sampling
-
Rennes, FranceCHU Rennes
Feb 2, 2023
Multiple Myeloma Trial in Augusta (Lenalidomide, Vitamin D - Intensified, Vitamin D - Therapeutic)
Not yet recruiting
- Multiple Myeloma
- Lenalidomide
- +2 more
-
Augusta, GeorgiaGeorgia Cancer Center at Augusta University
Apr 26, 2023
Obinutuzumab in Combination With Lenalidomide in Relapsed or
Recruiting
- Follicular Lymphoma
-
Tianjin, ChinaInstitute of Hematology and Blood Diseases Hospital ,Chinese Aca
Apr 27, 2023
Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))
Not yet recruiting
- Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
- intensity-modulated radiotherapy (IMRT)
- (no location specified)
Jun 4, 2023
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
- +7 more
Jan 9, 2023
Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)
Recruiting
- Multiple Myeloma
- Ixazomib plus low-dose lenalidomide
- Ixazomib
-
Hangzhou, Zhejiang, ChinaYang Xu
Feb 9, 2023
Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed/Refractory Marginal Zone Lymphoma
- Orelabrutinib
- +3 more
-
Guangzhou, Guangdong, China
- +10 more
Oct 8, 2023
Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)
Terminated
- Multiple Myeloma
- lenalidomide
- +3 more
-
Boston, Massachusetts
- +1 more
Nov 14, 2022